Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

PHASE4CompletedINTERVENTIONAL

Enrollment

310

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions

Osteoporotic FracturesOsteoporosis, Postmenopausal

Interventions

DRUG

Zoledronic acid

Annual intravenous 5.0 mg

DIETARY_SUPPLEMENT

vitamin D

800 IU daily

DIETARY_SUPPLEMENT

calcium

approximately 1200 mg (dietary and supplement)

OTHER

Saline

Annual intravenous saline placebo

Trial Locations (1)

University of Pittsburgh Osteoporosis Prevention & Treatment Center, New Kensington

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Susan L. Greenspan

OTHER

NCT02589600 - Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) | Biotech Hunter | Biotech Hunter